Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance

ExRNA

Table 1 MiRNAs as early diagnostic markers for pancreatic caner

Biomarker	Source	Sample size			Diagnostic utility		Ref.
Biomarker	Source	PaC	CP	Normal	Sensitivity	Specificity	Ref.
miR-18a	plasma	36		30	N/A	N/A	[44]
miR-192	serum	70		40	76.00%	55.00%	[46]
miR-196a	serum	35	15	15	100.00%	75.00%	[48]
miR-210	plasma	11		11	N/A	N/A	[41]
miR-221	plasma	47		30	74.00%	78.00%	[45]
miR-1290	serum	41	35	19	N/A	N/A	[52]
miRNA-192,-194	serum	N/A		N/A	84.00%	75.00%	[47]
miR-196a,b	serum	24	10	10	100.00%	90.00%	[50]
miR-200a	serum	45	11	32	84.40%	87.50%	[42]
miR-200b	serum	45	11	32	71.10%	96.90%	[42]
miR-148a, −216a,-217,181a/c, −324-5p, −146a,-210,-345,-574	blood	45	38	33	N/A	N/A	[61]
miR-20a,-21,-24,-25,-99a,-185,-191	serum	95		81	94.00%	93.00%	[62]
miR-21, −210, −155, −196a	plasma	28		19	64.00%	89.00%	[59]
miR-22,-642,-885-5p	blood	11		11	91.00%	91.00%	[64]
CA 19–9 and miR-27a-3p	serum/PBMCs	129	103	60	85.30%	81.60%	[66]
CA 19–9 and miR-16,-196a	serum/plasma	140	111	68	92.00%	95.60%	[67]
CA 19–9 and miR-145, −150, −223, −636	serum/blood	86	7	44	74.00%	96.00%	[68]
CA 19–9 and miR-26b, −34a, −22, −126-5p, −145, − 150, − 223, −505, − 636, − 885-5p	serum/blood	86	7	44	73.00%	97.00%	[68]

CA 19–9 Carbohydrate antigen 19–9, PaC Pancreatic cancer, CP Chronic pancreatitis

ISSN: 2398-0060